专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

11. 发明授权

US07329656B2 Arylthiobenzylpiperidine derivatives 失效
标题翻译：芳硫基苄基哌啶衍生物
公开(公告)号：US07329656B2
公开(公告)日：2008-02-12
申请号：US11231601
申请日：2005-09-21
申请人： Mohammad R. Marzabadi , Yu Jiang , Chien-An Chen , Kai Lu , Kim Andersen
发明人： Mohammad R. Marzabadi , Yu Jiang , Chien-An Chen , Kai Lu , Kim Andersen
IPC分类号： A61K31/4545 , A61K31/444 , A61K31/5377 , C07D211/04 , C07D401/04 , C07D413/14
CPC分类号： C07D401/04 , C07D211/26 , C07D211/62 , C07D401/12 , C07D401/14
摘要： This invention is directed to Arylthiobenzylpiperidine derivatives which are ligands at the MCH1 receptor. The invention provides a pharmaceutical composition comprising a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. This invention also provides a pharmaceutical composition made by admixing a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. This invention further provides a process for making a pharmaceutical composition comprising combining a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. This invention also provides a method of treating a subject suffering from depression and/or anxiety which comprises administering to the subject a therapeutically effective amount of a compound of the subject invention. This invention also provides a method of treating a subject suffering from obesity which comprises administering to the subject a therapeutically effective amount of a compound of the subject invention.
摘要翻译：本发明涉及作为MCH1受体的配体的芳硫基苄基哌啶衍生物。本发明提供了包含治疗有效量的本发明化合物和药学上可接受的载体的药物组合物。本发明还提供通过混合治疗有效量的本发明化合物和药学上可接受的载体制备的药物组合物。本发明还提供了制备药物组合物的方法，其包括将治疗有效量的本发明化合物和药学上可接受的载体组合。本发明还提供了治疗患有抑郁症和/或焦虑症的受试者的方法，其包括向受试者施用治疗有效量的本发明化合物。本发明还提供了治疗患有肥胖症的受试者的方法，其包括向受试者施用治疗有效量的本发明化合物。

12. 发明授权

US07105544B2 Substituted alkyl amido piperidines 失效
公开(公告)号：US07105544B2
公开(公告)日：2006-09-12
申请号：US10345063
申请日：2003-01-14
申请人： Mohammad R. Marzabadi , John M. Wetzel , Chien-An Chen , Yu Jiang , Kai Lu
发明人： Mohammad R. Marzabadi , John M. Wetzel , Chien-An Chen , Yu Jiang , Kai Lu
IPC分类号： A61K31/445 , C07D211/26
CPC分类号： C07D211/26 , C07D211/28 , C07D211/90 , C07D231/12 , C07D233/56 , C07D249/08 , C07D401/04 , C07D401/06 , C07D401/10 , C07D401/12 , C07D401/14 , C07D405/06 , C07D405/12 , C07D409/06 , C07D409/10 , C07D409/12 , C07D409/14 , C07D413/12 , C07D417/06 , C07D417/10 , C07D471/04 , C07D495/04
摘要： This invention is directed to compounds which are selective antagonists for melanin concentrating hormone-1 (MCH1) receptors. The invention provides a pharmaceutical composition comprising a therapeutically effective amount of the compound of the invention and a pharmaceutically acceptable carrier. This invention provides a pharmaceutical composition made by combining a therapeutically effective amount of the compound of this invention and a pharmaceutically acceptable carrier. This invention further provides a process for making a pharmaceutical composition comprising combining a therapeutically effective amount of the compound of the invention and a pharmaceutically acceptable carrier. This invention also provides a method of reducing the body mass of a subject which comprises administering to the subject an amount of a compound of the invention effective to reduce the body mass of the subject. This invention further provides a method of treating a subject suffering from depression and/or anxiety which comprises administering to the subject an amount of a compound of the invention effective to treat the subject's depression and/or anxiety.

13. 发明申请

US20060173027A1 Spirocvclic piperidines as mch1 antagonists and uses thereof 失效
标题翻译：作为mch1拮抗剂的西吡唑哌啶及其用途
公开(公告)号：US20060173027A1
公开(公告)日：2006-08-03
申请号：US10518939
申请日：2003-07-03
申请人： Mohammad Marzabadi , Yu Jiang , Kai Lu , Chien-An Chen , John De Leon , John Wetzel , Kim Andersen
发明人： Mohammad Marzabadi , Yu Jiang , Kai Lu , Chien-An Chen , John De Leon , John Wetzel , Kim Andersen
IPC分类号： A61K31/4747
CPC分类号： C07D221/20 , C07D401/06 , C07D401/12 , C07D405/12 , C07D409/12 , C07D413/12 , C07D491/10
摘要： This invention is directed to compounds which are selective antagonists for melanin concentrating hormone-1 (MCH1) receptors. The invention provides a pharmaceutical composition comprising a therapeutically effective amount of the compound of the invention and a pharmaceutically acceptable carrier. This invention provides a pharmaceutical composition made by combining a therapeutically effective amount of the compound of this invention and a pharmaceutically acceptable carrier. This invention further provides a process for making a pharmaceutical composition comprising combining a therapeutically effective amount of the compound of the invention and a pharmaceutically acceptable carrier. This invention also provides a method of reducing the body mass of a subject which comprises administering to the subject an amount of a compound of the invention effective to reduce the body mass of the subject. This invention further provides a method of treating a subject suffering from depression and/or anxiety which comprises administering to the subject an amount of a compound of the invention effective to treat the subject=s depression and/or anxiety. This invention further provides a method of treating a subject suffering from a urinary disorder.
摘要翻译：本发明涉及作为黑色素浓缩激素-1（MCH1）受体的选择性拮抗剂的化合物。本发明提供了包含治疗有效量的本发明化合物和药学上可接受的载体的药物组合物。本发明提供通过将治疗有效量的本发明化合物与药学上可接受的载体组合而成的药物组合物。本发明还提供了制备药物组合物的方法，其包括将治疗有效量的本发明化合物和药学上可接受的载体组合。本发明还提供减少受试者体重的方法，其包括向受试者施用一定量的有效减少受试者体重的本发明化合物。本发明进一步提供了治疗患有抑郁症和/或焦虑症的受试者的方法，其包括向受试者施用有效治疗受试者抑郁症和/或焦虑的量的本发明化合物。本发明还提供了治疗患有尿失禁的受试者的方法。

14. 发明申请

US20050157402A1 Projection display device for multimedia and wall display systems 有权
标题翻译：多媒体和墙壁显示系统的投影显示设备
公开(公告)号：US20050157402A1
公开(公告)日：2005-07-21
申请号：US11003252
申请日：2004-12-03
申请人： Ernesto Rodriguez , Patricia Hughes , William Haushalter , Kai Lu
发明人： Ernesto Rodriguez , Patricia Hughes , William Haushalter , Kai Lu
IPC分类号： G02B13/16 , G02B13/18 , G02B15/14 , G02B15/15
CPC分类号： G02B13/16 , G02B13/06 , G02B13/22 , G03B21/005
摘要： A front projection display device includes an optical engine including an illumination system, an imaging system, and projection optics. The projection optics include a first lens group of negative refractive power that has at least one aspheric surface. The projection optics output an image at a half field angle of at least 45°, where the image has substantially no distortion. For example, when the first lens group is placed at a distance of less than 1 meter from a viewing screen, the output image has a size of about 40 inches diagonal or greater, and requires substantially no keystone correction. In other aspects, the optical engine can be implemented in a wall-mounted projection system, a multimedia system, a compact integrated monitor system, and a portable projection unit.
摘要翻译：前投影显示装置包括具有照明系统，成像系统和投影光学元件的光学引擎。投影光学器件包括具有至少一个非球面的负屈光力的第一透镜组。投影光学器件以至少45°的半视角输出图像，其中图像基本上没有失真。例如，当将第一透镜组放置在距离观察屏幕小于1米的距离处时，输出图像具有约40英寸对角线或更大的尺寸，并且基本上不需要梯形失真校正。在其他方面，光学引擎可以实现在壁挂式投影系统，多媒体系统，小型集成监视器系统和便携式投影单元中。

15. 发明申请

US20050154022A1 4-aryl piperidines 审中-公开
标题翻译： 4-芳基哌啶
公开(公告)号：US20050154022A1
公开(公告)日：2005-07-14
申请号：US11034611
申请日：2005-01-13
申请人： Mohammad Marzabadi , John Wetzel , Chien-An Chen , John DeLeon , Yu Jiang , Kai Lu
发明人： Mohammad Marzabadi , John Wetzel , Chien-An Chen , John DeLeon , Yu Jiang , Kai Lu
IPC分类号： C07D211/26 , C07D401/12 , A61K31/4545 , C07D41/14
CPC分类号： C07D401/12 , C07D211/26
摘要： This invention is directed to 4-aryl piperidines and related heterocyclic compounds which are selective antagonists for melanin concentrating hormone-1 (MCH1) receptors. The invention provides a pharmaceutical composition comprising a therapeutically effective amount of the compound of the invention and a pharmaceutically acceptable carrier. This invention provides a pharmaceutical composition made by combining a therapeutically effective amount of the compound of this invention and a pharmaceutically acceptable carrier. This invention further provides a process for making a pharmaceutical composition comprising combining a therapeutically effective amount of the compound of the invention and a pharmaceutically acceptable carrier. This invention also provides a method of reducing the body mass of a subject which comprises administering to the subject an amount of a compound of the invention effective to reduce the body mass of the subject. This invention further provides a method of treating a subject suffering from depression and/or anxiety which comprises administering to the subject an amount of a compound of the invention effective to treat the subject's depression and/or anxiety.
摘要翻译：本发明涉及作为黑色素浓缩激素-1（MCH1）受体的选择性拮抗剂的4-芳基哌啶和相关的杂环化合物。本发明提供了包含治疗有效量的本发明化合物和药学上可接受的载体的药物组合物。本发明提供通过将治疗有效量的本发明化合物与药学上可接受的载体组合而成的药物组合物。本发明还提供了制备药物组合物的方法，其包括将治疗有效量的本发明化合物和药学上可接受的载体组合。本发明还提供减少受试者体重的方法，其包括向受试者施用一定量的有效减少受试者体重的本发明化合物。本发明进一步提供了治疗患有抑郁症和/或焦虑症的受试者的方法，其包括给予受试者一定量的有效治疗受试者的抑郁症和/或焦虑症的本发明化合物。

16. 发明授权

US12029860B1 Motion sickness prevention wristband and a control method thereof 有权
公开(公告)号：US12029860B1
公开(公告)日：2024-07-09
申请号：US18236918
申请日：2023-08-22
申请人： Hao Zheng , Ningning Gui , Sen Li , Kai Lu , Zhouming Zhu
发明人： Hao Zheng , Ningning Gui , Sen Li , Kai Lu , Zhouming Zhu
IPC分类号： A61M21/00 , A61N1/04 , A61N1/36
CPC分类号： A61M21/00 , A61N1/0472 , A61N1/36025 , A61M2021/0066 , A61M2021/0072 , A61M2205/07 , A61M2205/3344 , A61M2205/3368 , A61M2205/3379 , A61M2205/502 , A61M2209/088
摘要： The present invention discloses a motion sickness prevention wristband and a control method thereof, wherein the motion sickness prevention wristband comprises wristband body, and further comprises microcontroller unit MCU, pressure sensor, electrode assembly, and air bag control assembly; pressure sensor, electrode assembly, and air bag control assembly are electrically connected to the MCU, and air bag control assembly is resisted against electrode assembly; pressure sensor, for obtaining contact pressure value between electrode assembly and the surface of the human skin; the MCU, for determining air pressure control data; and air bag control assembly, control air pressure change to enable the MCU to apply electrical stimulation to electrode assembly after the air pressure change. The air pressure change enables electrode assembly to better adhere to the skin, the electrical stimulation performed can maintain contact resistance, keep the electrical stimulation, thereby significantly enhancing the effect of anti-motion sickness.

17. 发明授权

US07199135B2 Substituted alkyl amido piperidines 失效
标题翻译：取代的烷基酰氨基哌啶
公开(公告)号：US07199135B2
公开(公告)日：2007-04-03
申请号：US10753057
申请日：2004-01-06
申请人： Mohammad R. Marzabadi , John M. Wetzel , Chien-An Chen , Yu Jiang , Kai Lu
发明人： Mohammad R. Marzabadi , John M. Wetzel , Chien-An Chen , Yu Jiang , Kai Lu
IPC分类号： A61K31/445 , C07D401/04
CPC分类号： C07D211/26 , C07D211/28 , C07D211/90 , C07D231/12 , C07D233/56 , C07D249/08 , C07D401/04 , C07D401/06 , C07D401/10 , C07D401/12 , C07D401/14 , C07D405/06 , C07D405/12 , C07D409/06 , C07D409/10 , C07D409/12 , C07D409/14 , C07D413/12 , C07D417/06 , C07D417/10 , C07D471/04 , C07D495/04
摘要： This invention is directed to compounds which are selective antagonists for melanin concentrating hormone-1 (MCH1) receptors. The invention provides a pharmaceutical composition comprising a therapeutically effective amount of the compound of the invention and a pharmaceutically acceptable carrier. This invention provides a pharmaceutical composition made by combining a therapeutically effective amount of the compound of this invention and a pharmaceutically acceptable carrier. This invention further provides a process for making a pharmaceutical composition comprising combining a therapeutically effective amount of the compound of the invention and a pharmaceutically acceptable carrier. This invention also provides a method of reducing the body mass of a subject which comprises administering to the subject an amount of a compound of the invention effective to reduce the body mass of the subject. This invention further provides a method of treating a subject suffering from depression and/or anxiety which comprises administering to the subject an amount of a compound of the invention effective to treat the subject's depression and/or anxiety.
摘要翻译：本发明涉及作为黑色素浓缩激素-1（MCH1）受体的选择性拮抗剂的化合物。本发明提供了包含治疗有效量的本发明化合物和药学上可接受的载体的药物组合物。本发明提供通过将治疗有效量的本发明化合物与药学上可接受的载体组合而成的药物组合物。本发明还提供了制备药物组合物的方法，其包括将治疗有效量的本发明化合物和药学上可接受的载体组合。本发明还提供减少受试者体重的方法，其包括向受试者施用一定量的有效减少受试者体重的本发明化合物。本发明进一步提供了治疗患有抑郁症和/或焦虑症的受试者的方法，其包括给予受试者一定量的有效治疗受试者的抑郁症和/或焦虑症的本发明化合物。

18. 发明申请

US20060217418A1 Substituted alkyl amido piperidines 审中-公开
公开(公告)号：US20060217418A1
公开(公告)日：2006-09-28
申请号：US10541991
申请日：2004-01-06
申请人： Mohammad Marzabadi , John Wetzel , Chien-An Chen , Yu Jiang , Kai Lu
发明人： Mohammad Marzabadi , John Wetzel , Chien-An Chen , Yu Jiang , Kai Lu
IPC分类号： A61K31/445 , C07D211/26
CPC分类号： C07D211/26 , C07D211/28 , C07D211/90 , C07D231/12 , C07D233/56 , C07D249/08 , C07D401/04 , C07D401/06 , C07D401/10 , C07D401/12 , C07D401/14 , C07D405/06 , C07D405/12 , C07D409/06 , C07D409/10 , C07D409/12 , C07D409/14 , C07D413/12 , C07D417/06 , C07D417/10 , C07D471/04 , C07D495/04
摘要： This invention is directed to compounds which are selective antagonists for melanin concentrating hormone-1 (MCH1) receptors. The invention provides a pharmaceutical composition comprising a therapeutically effective amount of the compound of the invention and a pharmaceutically acceptable carrier. This invention provides a pharmaceutical composition made by combining a therapeutically effective amount of the compound of this invention and a pharmaceutically acceptable carrier. This invention further provides a process for making a pharmaceutical composition comprising combining a therapeutically effective amount of the compound of the invention and a pharmaceutically acceptable carrier. This invention also provides a method of reducing the body mass of a subject which comprises administering to the subject an amount of a compound of the invention effective to reduce the body mass of the subject. This invention further provides a method of treating a subject suffering from depression and/or anxiety which comprises administering to the subject an amount of a compound of the invention effective to treat the subject's depression and/or anxiety.

19. 发明授权

US07067534B1 Substituted anilinic piperidines as MCH selective antagonists 失效
标题翻译：取代的苯胺哌啶类作为MCH选择性拮抗剂
公开(公告)号：US07067534B1
公开(公告)日：2006-06-27
申请号：US10719358
申请日：2003-11-21
申请人： Mohammad R. Marzabadi , John Wetzel , John E. DeLeon , Yu Jiang , Chien-An Chen , Kai Lu
发明人： Mohammad R. Marzabadi , John Wetzel , John E. DeLeon , Yu Jiang , Chien-An Chen , Kai Lu
IPC分类号： A61K31/445 , C07D401/06
CPC分类号： C07D401/04 , C07D211/26 , C07D211/28 , C07D211/90 , C07D401/06 , C07D401/10 , C07D401/12 , C07D401/14 , C07D405/06 , C07D405/12 , C07D409/06 , C07D409/12 , C07D409/14 , C07D413/06 , C07D413/12 , C07D417/06 , C07D417/10 , C07D471/04 , C07D495/04
摘要： This invention is directed to compounds which are selective antagonists for melanin concentrating hormone-1 (MCH1) receptors. The invention provides a pharmaceutical composition comprising a therapeutically effective amount of the compound of the invention and a pharmaceutically acceptable carrier. This invention provides a pharmaceutical composition made by combining a therapeutically effective amount of the compound of this invention and a pharmaceutically acceptable carrier. This invention further provides a process for making a pharmaceutical composition comprising combining a therapeutically effective amount of the compound of the invention and a pharmaceutically acceptable carrier.
摘要翻译：本发明涉及作为黑色素浓缩激素-1（MCH1）受体的选择性拮抗剂的化合物。本发明提供了包含治疗有效量的本发明化合物和药学上可接受的载体的药物组合物。本发明提供通过将治疗有效量的本发明化合物与药学上可接受的载体组合而成的药物组合物。本发明还提供了制备药物组合物的方法，其包括将治疗有效量的本发明化合物和药学上可接受的载体组合。

20. 发明申请

US20060079683A1 Arylthiobenzylpiperidine derivatives 审中-公开
标题翻译：芳硫基苄基哌啶衍生物
公开(公告)号：US20060079683A1
公开(公告)日：2006-04-13
申请号：US10961432
申请日：2004-10-08
申请人： Mohammad Marzabadi , Yu Jiang , Chien-An Chen , Kai Lu , Kim Andersen
发明人： Mohammad Marzabadi , Yu Jiang , Chien-An Chen , Kai Lu , Kim Andersen
IPC分类号： C07D413/14 , C07D401/14
CPC分类号： C07D211/60 , C07D211/26 , C07D401/04 , C07D401/12 , C07D401/14
摘要： This invention is directed to Arylthiobenzylpiperidine derivatives which are ligands at the MCH1 receptor. The invention provides a pharmaceutical composition comprising a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. This invention also provides a pharmaceutical composition made by admixing a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. This invention further provides a process for making a pharmaceutical composition comprising combining a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. This invention also provides a method of treating a subject suffering from depression and/or anxiety which comprises administering to the subject an amount of a compound of the subject invention. This invention also provides a method of treating a subject suffering from obesity which comprises administering to the subject an amount of a compound of the subject invention.
摘要翻译：本发明涉及作为MCH1受体的配体的芳硫基苄基哌啶衍生物。本发明提供了包含治疗有效量的本发明化合物和药学上可接受的载体的药物组合物。本发明还提供通过混合治疗有效量的本发明化合物和药学上可接受的载体制备的药物组合物。本发明还提供了制备药物组合物的方法，其包括将治疗有效量的本发明化合物和药学上可接受的载体组合。本发明还提供了治疗患有抑郁症和/或焦虑症的受试者的方法，其包括给予受试者一定量的本发明化合物。本发明还提供了治疗患有肥胖症的受试者的方法，其包括给予受试者一定量的本发明化合物。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式